IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for Myeloma Small retrospective study finds fewer severe infections during periods of replacement therapy Sep 29, 2023
Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening News, features, and commentary about cancer-related issues Sep 28, 2023
Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myeloma Motixafortide plus filgrastim increased adequate harvest rate from 9.5% to 67.5% Sep 11, 2023
Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care News, features, and commentary about cancer-related issues Sep 07, 2023
Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma Mezigdomide led to 41% response rate in heavily pretreated patients Aug 30, 2023
Nurse Suspected of Poisoning; Hospital Mask Mandates Return; Congressman's Cancer Dx Health news and commentary from around the Web gathered by 51³ΙΘΛΆ―Βώ staff Aug 30, 2023
WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer News, features, and commentary about cancer-related issues Jun 29, 2023
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets Jun 05, 2023
Novel Antibody Induces Durable Responses in Heavily Pretreated Myeloma Overall response rate of 90% in patients who received highest doses of REGN5459 Apr 18, 2023
Novel 'Off the Shelf' CAR-T Product Shows Promise in Myeloma Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products Feb 02, 2023
Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma No increased risk to patients with other hematologic malignancies, meta-analysis shows Nov 02, 2022
FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
Bispecific Antibody Active in Heavily Treated Multiple Myeloma Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
Studies Reinforce Prognostic Role for Circulating Tumor Cells in Myeloma At higher levels, different cutoffs show at least a doubling of PFS, OS hazard ratios Jun 13, 2022
Myeloma Trial Supports 'Personalized Approach' to Upfront Transplant DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored Jun 06, 2022
Unprecedented PFS Improvement in Relapsed Multiple Myeloma Three-year median with addition of isatuximab to proteasome inhibitor backbone May 26, 2022
Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma Study failed to replicate positive results seen in relapsed/refractory setting May 11, 2022
Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
Case of Parkinson's-Like Symptoms in Myeloma Patient After CAR-T Product FDA advises monitoring patients after T-cell infusion for signs, symptoms of neurotoxicity Dec 10, 2021
Is Multiple Myeloma a Greater Threat to Black Patients? Incidence and treatment disparities combined with a heightened COVID risk is cause for concern Nov 11, 2021
Rare Case of Multiple Myeloma in Teenage Girl Successful use of affordable induction therapy with autologous stem cell transplantation Nov 09, 2021
Myeloma Drug Pulled From Market Just Months After Approval Data from confirmatory trial failed to make a compelling case for full FDA approval Oct 22, 2021
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma Prolonging PFS a positive, as advances make OS improvement harder to achieve Jun 18, 2021
Charles Grodin's Death From Multiple Myeloma A look at the beloved actor's highly treatable but rarely curable disease Jun 02, 2021
Three-Drug Regimen Reduces Myeloma Treatment Burden Efficacy maintained with addition of SQ daratumumab to pomalidomide, dexamethasone Dec 04, 2020
FDA OKs Anti-BCMA Drug for Multiple Myeloma Accelerated approval for belantamab mafodotin after four other therapies Aug 06, 2020
Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
New Standard for Relapsed/Refractory Multiple Myeloma? Triplet regimen significantly extended median PFS versus doublet in IKEMA study Jun 15, 2020
High Marks for CAR T Cells in R/R Myeloma Response rates of 70-100% with BCMA-targeted products for heavily treated disease Jun 03, 2020
VRd Still Reigns in Newly Diagnosed Myeloma KRd fails to prove superiority in head-to-head trial Jun 01, 2020
COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
